Advers Reactions to Radiopharmaceuticals: Kidney Imaging Radiopharmaceuticals

eczacilikbilimleri-1-2-2021

Merve SELOĞLUa, Asuman Yekta ÖZERa

aHacettepe University Faculty of Pharmacy, Deparmant of Radiopharmacy, Ankara, TURKEY

ABSTRACT
Radiopharmaceuticals are special kind of drugs prepared by radiopharmasists in Nuclear Medicine departments used in diagnosis and treatment of human diseases. There are two parts in their structure: radioactive and pharmaceutical. They are administered intravenously to the patient. Therefore, parenteral preparations need to fulfill the specifications. Essentially, radiopharmaceuticals are used in the imaging of many organs mainly. They have an important role especially in kidney imaging studies. The most commonly used radiopharmaceuticals in kidney imaging are 99mTc-DTPA, 131I-hipuran (131I-OIH) and 99mTc-MAG3. To a lesser extent, 99mTc-DMSA, 99mTc-Gluceptate, 51Cr-EDTA and different radiopharmaceuticals like 99mTc-(CO3) NTA, 125I-Iothalamat are also used. Some adverse effects are seen in radiopharmaceuticals, even if it is less frequently than conventional drugs. However, adverse effects that may result in death, can also be seen. Adverse Reactions to Radiopharmaceuticals (ARRP) should be taken into consideration during their application and these adverse reactions should be notified to the relevant authorities when necessary. In this study, the importance of the adverse reactions seen in the use of the compounds will be discussed and the adverse effects seen especially in radiopharmaceuticals used in kidney imaging will be evaluated.
Keywords: Radiopharmaceuticals; drug-related side effects and adverse reactions; kidney

Referanslar

  1. Pinto SR, Santos LFC, Reis SRR, bastos MK, Gomes VS, Vieira TO, et.al. Adverse reactions to radiopharmaceuticals: a survey based on clinical cases using criteria of systematic review. Therapeutic Innovation and Regulatory Science. 2017;52(1):109-13. [Crossref]  [PubMed]
  2. Atak İE, Özer Ay, Radyofarmasötiklerde karşılaşılan ters ilaç reaksiyonları. Hacettepe Univ J Pharm. 2003;23:33-58.
  3. Shepherd G, Mohorn P, yacoub K, et al. Adverse drug reaction deaths reported in United States vital statistics, 1999-2006. Ann Pharmacother. 2012;46:169-75. [Crossref]  [PubMed]
  4. Sampson, Cb. Adverse reactions and drug ınteractions with radiopharmaceuticals. Drug Saf. 1993;8:280-94. [Crossref]  [PubMed]
  5. Saha Gb. Adverse reactions to radiopharmaceuticals and altered biodistribution of radiopharmaceuticals. In: Saha Gb, ed. Fundamentals of Nuclear Pharmacy. New york: Springer; 2004. p.351-3.
  6. Perales JLG, Martínez AA. A portable database of adverse reactions and drug ınteractions with radiopharmaceuticals. J Nucl Med Technol. 2013;41:212-5. [Crossref]  [PubMed]
  7. Laroche ML, quelven I, Mazère J, Merle L. Adverse reactions to radiopharmaceuticals in France: analysis of the national pharmacovigilance database. Annals of Pharmacotherapy. 2014;49:39-47. [Crossref]  [PubMed]
  8. Matsuda H, Uehara T, Okazawa H, Mizumura S, yokoyama K, yoshimura M. The 40th report on survey of the adverse reactions to radiopharmaceuticals (the 43rd survey in 2017). Kakuigaku. 2019;56:15-23.
  9. Kumar R, Kalaiselvan V, Kumar R, Verma R, Singh GN. Pharmacovigilance in radiopharmaceuticals. Indian J Nucl Med. 2016;31:89-92. [Crossref]  [PubMed]  [PMC]
  10. Schreuder N, Koopman D, Jager PL, Kosterink JGW, Puijenbroek E. Adverse events of diagnostic radiopharmaceuticals: a systematic review. Semin Nucl Med. 2019;9:382-410. [Crossref]  [PubMed]
  11. Hesslewood SR, Keeling DH. Frequency of adverse reactions to radiopharmaceuticals in Europe. Eur J Nucl Med. 1997;24:1179-82. [Crossref]  [PubMed]
  12. Hesslewood S, Leung E. Drug interactions with radiopharmaceuticals. Eur J Nucl Med. 1994;21:348-56. [Crossref]  [PubMed]
  13. Vallabhajosula S, Killeen RP, Osborne JR. Altered biodistribution of radiopharmaceuticals: role of radiochemical/pharmaceutical purity, physiological, and pharmacologic factors. Semin Nucl Med. 2010;40:220-41. [Crossref]  [PubMed]
  14. Oliveira RS. Undesirable events with radiopharmaceuticals. The Tohoku Journal of Experimental Medicine. 2009;217:251-7. [Crossref]  [PubMed]
  15. Erbaş b. Nefroürolojide görüntüleme: dünü, bugünü, yarını. Nucl Med Semin. 2019;5:169- 72.
  16. Szabo Z, Alachkar N, Xia J, Mathews Wb, Rabb H. Molecular imaging of the kidneys. Seminers in Nuclear Medicine. 2011;41:20-8. [Crossref]  [PubMed]  [PMC]
  17. Taylor AT. Radionuclides in nephrourology, part 1: radiopharmaceuticals, quality control, and quantitative ındices. J Nucl Med. 2014;55:608- 15. [Crossref]  [PubMed]  [PMC]
  18. Mohammadi b, Shirmardi SP, Shokri AA, Erfani M. Estimation of organ-absorbed doses in human from gamma rays of 99mTc-DTPA radiopharmaceutical, using the animal dissection data. Archives of Advances in biosciences. 2019;10:22-30.
  19. European system for reporting adverse reactions to and defects in radiopharmaceuticals: annual report 2000. Eur J Nucl Med. 2002; 29:13- 9. [Crossref]  [PubMed]
  20. Hauser W, Atkins HL, Nelson KG, Richards P. Technetium-99m DTPA: a new radiopharmaceutical for brain and kidney scanning. Radiology. 1970;94:679-84. [Crossref]  [PubMed]
  21. Silindir M, Özer Ay. Adverse Reactions to Radiopharmaceuticals (ARRP): particularly to technetium radiopharmaceuticals. FAbAD J Pharm Sci. 2008;33:109-17.
  22. Silberstein Eb. Adverse reactions to radiopharmaceuticals. In: Silberstein Eb, ed. Correspondence Continuing Education Courses for Nuclear Pharmacists and Nuclear Medicine Professionals. New Mexico: University of New Mexico Pharmacy Continuing Education Albuquerque; 1996.
  23. Kennedy-Dixon TG, Gossell-Williams M, Cooper M, Trabelsi M, Vinjamuri S. Evaluation of radiopharmaceutical adverse reaction reports to the british Nuclear Medicine society from 2007 to 2016. J Nucl Med. 2017;58:2010-2. [Crossref]  [PubMed]
  24. b. Rosenthall L. Ortho-Iodohippurate-I131 kidney scanning in renal failure. Radiology. 1996;87:298- 303. [Crossref]  [PubMed]
  25. bih LI, Changlai SP, Ho CC, Lee SP. Application of radioisotope renography with technetium- 99m mercaptoacetylthreeglycine on patients with spinal cord injuries. Arch Phys Med Rehabil. 1994;75:982-6. [Crossref]  [PubMed]
  26. Stockel M, Ennow K, Kristensen K, Rodbro P. Anaphylactic reaction to orthoiodohippurate. Eur J Nucl Med. 1983;8:89-90. [Crossref]  [PubMed]
  27. Mititelu R, bratu O. Radionuclide imaging. An update on the use of dynamic renal scintigraphy. Modern Medicine. 2017;24(4):199-203. [Crossref]
  28. A. Tylor A, Ziffer JA, Steves A, Eshima D, Delaney Vb, Velchel JD. Clinical comparison of I-131 orthoiodohippurate and the kit formulation of Tc99m mercaptoacetyltriglycine. Radiology. 1989;170:721-5. [Crossref]  [PubMed]
  29. Monograph for Technetium (99mTc) Succimer Complex Injection 3, WHO, September 2017.
  30. Keeling DH. Adverse reactions to radiopharmaceuticals United Kingdom 1977-1983. brit J Radiol. 1984; 57: 1091-6. [Crossref]  [PubMed]